The decision makers in Access-Ad obviously thought high enough of our data to make it one of the few drugs to be included in this initiative. So, they definitely reviewed the data. How do they justify and entice people to participate in a trial if our drug is ultimately rejected? Hey, we have this drug that failed. You wanna participate in the study? Heck no. But we think it could be beneficial to some patients. So, why wasn’t it approve for them? Ugh ugh. Well it does reduce brain atrophy and one group had Alz nearly halted altogether. And it still wasn’t approved? What aren’t you telling us? Smells fishy
Market Data 
Markets 
AI
